Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-18 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
G | Common Stock | D | 28328 | $0.00 - $0.00 | $0 |
| 2024-04-08 | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal
(Chief Scientific Officer) |
S | Common Stock | D | 69107 | $54.12 - $54.92 | $3,743,605 |
| 2024-04-08 | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal
(Chief Scientific Officer) |
M | Common Stock | A | 69107 | $3.76 - $3.76 | $259,842 |
| 2024-04-01 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
S | Common Stock | D | 4000 | $58.66 - $58.66 | $234,640 |
| 2024-04-01 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
M | Common Stock | A | 4000 | $10.03 - $10.03 | $40,120 |
| 2024-03-19 | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair
(Director) |
S | Common Stock | D | 18681 | $57.18 - $57.18 | $1,068,160 |
| 2024-03-15 | Apellis Pharmaceuticals, Inc. | Chopas James George
(VP/Chief Accounting Officer) |
S | Common Stock | D | 184 | $56.46 - $56.46 | $10,388 |
| 2024-03-13 | Apellis Pharmaceuticals, Inc. | Nicholson Nur
(Chief Technical Officer) |
S | Common Stock | D | 11220 | $57.31 - $58.13 | $645,836 |
| 2024-03-08 | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal
(Chief Scientific Officer) |
S | Common Stock | D | 69107 | $61.88 - $63.35 | $4,297,548 |
| 2024-03-08 | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal
(Chief Scientific Officer) |
M | Common Stock | A | 69107 | $3.67 - $3.67 | $253,622 |
| 2024-03-06 | Apellis Pharmaceuticals, Inc. | Watson David O.
(General Counsel) |
M | Common Stock | A | 3762 | $13.85 - $13.85 | $52,103 |
| 2024-02-12 | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey
(Chief Business & Strat Officer) |
S | Common Stock | D | 597 | $67.77 - $67.77 | $40,456 |
| 2024-01-29 | Apellis Pharmaceuticals, Inc. | Watson David O.
(General Counsel) |
S | Common Stock | D | 906 | $64.14 - $64.14 | $58,109 |
| 2024-01-29 | Apellis Pharmaceuticals, Inc. | Townsend Adam J.
(Chief Commercial Officer) |
S | Common Stock | D | 906 | $64.14 - $64.14 | $58,109 |
| 2024-01-29 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
S | Common Stock | D | 906 | $64.14 - $64.14 | $58,109 |
| 2024-01-29 | Apellis Pharmaceuticals, Inc. | Lewis Karen
(Chief People Officer) |
S | Common Stock | D | 1250 | $64.14 - $65.53 | $81,400 |
| 2024-01-29 | Apellis Pharmaceuticals, Inc. | Francois Cedric
(Chief Executive Officer) |
S | Common Stock | D | 2843 | $64.14 - $64.14 | $182,344 |
| 2024-01-29 | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey
(Chief Business & Strat Officer) |
S | Common Stock | D | 367 | $64.14 - $64.14 | $23,538 |
| 2024-01-23 | Apellis Pharmaceuticals, Inc. | Lewis Karen
(Chief People Officer) |
S | Common Stock | D | 4286 | $63.69 - $63.69 | $272,975 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Francois Cedric
(Chief Executive Officer) |
S | Common Stock | D | 13431 | $65.00 - $65.00 | $872,961 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Watson David O.
(General Counsel) |
S | Common Stock | D | 4184 | $65.00 - $65.00 | $271,943 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Townsend Adam J.
(Chief Commercial Officer) |
S | Common Stock | D | 3413 | $65.00 - $65.00 | $221,831 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
S | Common Stock | D | 3551 | $65.00 - $65.00 | $230,800 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Nicholson Nur
(Chief Technical Officer) |
S | Common Stock | D | 2593 | $65.00 - $65.00 | $168,534 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Lewis Karen
(Chief People Officer) |
S | Common Stock | D | 1738 | $65.00 - $65.00 | $112,963 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey
(Chief Development Officer) |
S | Common Stock | D | 1607 | $65.00 - $65.00 | $104,448 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal
(Chief Scientific Officer) |
S | Common Stock | D | 3913 | $65.00 - $65.00 | $254,329 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey
(Chief Business & Strat Officer) |
S | Common Stock | D | 1384 | $65.00 - $65.00 | $89,954 |
| 2024-01-22 | Apellis Pharmaceuticals, Inc. | Chopas James George
(VP/Chief Accounting Officer) |
S | Common Stock | D | 1061 | $65.00 - $65.00 | $68,960 |
| 2024-01-17 | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey
(Chief Development Officer) |
S | Common Stock | D | 5207 | $65.58 - $65.58 | $341,475 |
| 2024-01-17 | Apellis Pharmaceuticals, Inc. | Lewis Karen
(Chief People Officer) |
S | Common Stock | D | 3276 | $65.58 - $65.58 | $214,840 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal
(Chief Scientific Officer) |
S | Common Stock | D | 1632 | $66.81 - $66.81 | $109,031 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal
(Chief Scientific Officer) |
A | Common Stock | A | 6743 | $0.00 - $0.00 | $0 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Chopas James George
(VP/Chief Accounting Officer) |
S | Common Stock | D | 864 | $66.81 - $66.81 | $57,722 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Chopas James George
(VP/Chief Accounting Officer) |
A | Common Stock | A | 8312 | $0.00 - $0.00 | $0 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Lewis Karen
(Chief People Officer) |
S | Common Stock | D | 1632 | $66.81 - $66.81 | $109,031 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Lewis Karen
(Chief People Officer) |
A | Common Stock | A | 16963 | $0.00 - $0.00 | $0 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Watson David O.
(General Counsel) |
S | Common Stock | D | 4240 | $66.81 - $66.81 | $283,268 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Watson David O.
(General Counsel) |
A | Common Stock | A | 23748 | $0.00 - $0.00 | $0 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Townsend Adam J.
(Chief Commercial Officer) |
S | Common Stock | D | 2235 | $66.81 - $66.81 | $149,317 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Townsend Adam J.
(Chief Commercial Officer) |
A | Common Stock | A | 23748 | $0.00 - $0.00 | $0 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
S | Common Stock | D | 2235 | $66.81 - $66.81 | $149,317 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
A | Common Stock | A | 23748 | $0.00 - $0.00 | $0 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey
(Chief Development Officer) |
S | Common Stock | D | 438 | $66.81 - $66.81 | $29,262 |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey
(Chief Development Officer) |
A | Common Stock | A | 19508 | $0.00 - $0.00 | $0 |
| 2024-01-01 | Apellis Pharmaceuticals, Inc. | O'Brien Stephanie...
(Director) |
A | Common Stock | A | 3341 | $0.00 - $0.00 | $0 |
| 2023-12-26 | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey
(Chief Development Officer) |
S | Common Stock | D | 303 | $57.86 - $60.23 | $18,088 |
| 2023-12-19 | Apellis Pharmaceuticals, Inc. | Watson David O.
(General Counsel) |
S | Common Stock | D | 3905 | $57.00 - $57.38 | $223,471 |
| 2023-12-19 | Apellis Pharmaceuticals, Inc. | Watson David O.
(General Counsel) |
M | Common Stock | A | 7905 | $13.85 - $13.85 | $109,484 |
| 2023-12-14 | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair
(Director) |
M | Common Stock | A | 6274 | $13.19 - $13.19 | $82,754 |
| 2023-12-01 | Apellis Pharmaceuticals, Inc. | Townsend Adam J.
(Chief Commercial Officer) |
S | Common Stock | D | 110000 | $60.50 - $61.31 | $6,689,302 |
| 2023-12-01 | Apellis Pharmaceuticals, Inc. | Townsend Adam J.
(Chief Commercial Officer) |
M | Common Stock | A | 110000 | $15.09 - $15.09 | $1,659,900 |
| 2023-11-30 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
S | Common Stock | D | 14158 | $54.73 - $54.79 | $774,883 |
| 2023-11-30 | Apellis Pharmaceuticals, Inc. | Sullivan Timothy ...
(Chief Financial Officer) |
M | Common Stock | A | 14158 | $10.03 - $10.03 | $142,004 |
| 2023-11-21 | Apellis Pharmaceuticals, Inc. | Francois Cedric
(Chief Executive Officer) |
S | Common Stock | D | 5000 | $48.80 - $48.80 | $244,000 |
| 2023-11-17 | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair
(Director) |
S | Common Stock | D | 8894 | $49.99 - $49.99 | $444,619 |
| 2023-10-17 | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair
(Director) |
S | Common Stock | D | 24000 | $49.00 - $49.00 | $1,176,000 |
| 2023-11-17 | Apellis Pharmaceuticals, Inc. | Machiels Alec
(Director) |
S | Common Stock | D | 1250 | $47.74 - $47.74 | $59,675 |
| 2023-11-17 | Apellis Pharmaceuticals, Inc. | Machiels Alec
(Director) |
M | Common Stock | A | 1250 | $2.67 - $2.67 | $3,337 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |